Upper extremity study showed that EXPAREL significantly reduces pain scores and opioid use Lower extremity study defined safety and pharmacokinetic profile through 120 hours Timing for resubmission of ...
— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...
TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced ...
-- Advances global expansion strategy to minimize postsurgical opioid use worldwide -- PARSIPPANY, N.J., June 25, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (“Pacira”) (NASDAQ: PCRX) today ...
In both studies, Exparel achieved a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine hydrochloride. The Food and Drug Administration (FDA) has ...
The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...
TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results